Parnassus Value Select ETF (PRVS) news
Recent news
Denali Therapeutics enters agreement to sell rare pediatric disease priority review voucher for $195 million
Denali Therapeutics has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million, according to recent disclosures. The PRV was awarded by the U.S. Food and Drug Administration (FDA) under the Rare Pediatric Disease PRV program, which incentivizes…
AInvest Wire · Jun 18, 2026Rocket Pharmaceuticals announces closing of sale of rare pediatric disease priority review voucher for $180 million
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $180 million, providing non-dilutive capital to support its cardiovascular gene therapy pipeline. The PRV was awarded following the FDA’s accelerated approval of…
AInvest Wire · Jun 12, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.